Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience (Q41506217)

1 October 2017

Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

1 October 2017

0 references

1 reference

1 reference

1 reference

Ryan B Perumpail

1

1 reference

1 October 2017

Robert J Wong

series ordinal

2

1 reference

1 October 2017

Aijaz Ahmed

series ordinal

3

1 reference

1 October 2017

Stephen A Harrison

series ordinal

4

1 reference

1 October 2017

7 August 2015

1 reference

Digestive Diseases and Sciences

1 October 2017

1 reference

1 October 2017

60

1 reference

1 October 2017

3142-3148

1 reference

1 October 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-015-3821-7

1 October 2017

0 references

cites work

Prevalence and trends in obesity among US adults, 1999-2008

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Features, diagnosis, and treatment of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Increasing prevalence of the metabolic syndrome among u.s. Adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Nonalcoholic fatty liver disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Pathology of fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Obesity, Inflammation, and Insulin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

STAT3 activation in monocytes accelerates liver cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Pharmacological characterization of a small molecule inhibitor of c-Jun kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-015-3821-7

Leptin and liver fibrosis: A matter of fat

21 January 2018

1 reference

12 December 2020

Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review

1 reference

12 December 2020

NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States

1 reference

12 December 2020

Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?

1 reference

12 December 2020

Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women.

1 reference

12 December 2020

10.1007/S10620-015-3821-7

Identifiers

DOI

1 reference

1 October 2017

1 reference